Patents by Inventor FRANCOISE MEYLAN

FRANCOISE MEYLAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease
    Patent number: 10590201
    Abstract: Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: March 17, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard M. Siegel, Francoise Meylan, Yun-Jeong Song
  • ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES
    Publication number: 20180186888
    Abstract: Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.
    Type: Application
    Filed: January 16, 2018
    Publication date: July 5, 2018
    Inventors: RICHARD M. SIEGEL, FRANCOISE MEYLAN, YUN-JEONG SONG
  • Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
    Patent number: 9896511
    Abstract: Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: February 20, 2018
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard M. Siegel, Francoise Meylan, Yun-Jeong Song
  • ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES
    Publication number: 20160053007
    Abstract: Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.
    Type: Application
    Filed: November 3, 2015
    Publication date: February 25, 2016
    Inventors: RICHARD M. SIEGEL, FRANCOISE MEYLAN, YUN-JEONG SONG
  • Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
    Patent number: 9068003
    Abstract: Provided are methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: June 30, 2015
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard M Siegel, Francoise Meylan, Yun-Jeong Song
  • BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF
    Publication number: 20120263718
    Abstract: Provided are methods and compositions for treating inflammatory autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).
    Type: Application
    Filed: March 13, 2012
    Publication date: October 18, 2012
    Inventors: RICHARD M. SIEGEL, FRANCOISE MEYLAN, YUN-JEONG SONG
  • BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY
    Publication number: 20110217310
    Abstract: Provided is a method and compositions for of treating an inflammatory or autoimmune disease in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).
    Type: Application
    Filed: January 10, 2008
    Publication date: September 8, 2011
    Inventors: RICHARD M. SIEGEL, FRANCOISE MEYLAN